Developing scalable, first-in-class tri-specific nanobody T‑cell engagers and in vivo nanobody-based CAR‑T therapies
Breakthrough Trident platforms driving next-generation cancer and autoimmune treatments
With Sidocel's innovative, next-generation immunotherapies, we’re redefining efficacy and safety through more targeted, effective, and safer interventions.